SLSN

NASDAQ

Solesence Inc.

SectorConsumer DiscretionaryIndustryPackage Goods/Cosmetics

$1.20+0.09 (+8.14%)

News25/Ratings0

Price$1.20+0.11 (+10.65%)

02:30 PM07:45 PM

News · 26 weeks15-75%

2025-11-022026-04-26

Mix690d

SEC Filings3(50%)
Earnings2(33%)
Leadership1(17%)

Latest news

25 items

2dSEC
Amendment: SEC Form 10-K/A filed by Solesence Inc.
10-K/A - SOLESENCE, INC. (0000883107) (Filer)
25dSEC
SEC Form 10-K filed by Solesence Inc.
10-K - SOLESENCE, INC. (0000883107) (Filer)
25dSEC
Solesence Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
25dPR
Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results
Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2025. "In 2025, we achieved record revenue of $62.1 million, effectively doubling our line of consumer products in just two years. This affirmed both the value we bring to the industry, and our ability to establish ourselves as a leading innovator and manufacturer of SPF-infused beauty products," said Kevin Cureton, President and Chief Executive Officer. "In November, we launc
37dPR
Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026
ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 31, 2026, and host a conference call and webcast on the same date. Fourth Quarter 2025 Conference Call DetailsDate / Time: Tuesday, March 31, 2026 – 7:30 a.m. CT, 8:30 a.m. ET Speakers: Kevin Cureton, President & CEO and Laura Riffner, Chief Financial Officer Webcast Link: https://edge.media-server.com/mmc/p/btv3gq6b Dial-In Link: https://register-conf.media-server.com/re
58dPR
Yoolie Park joins Solésence, Inc. as Vice President of Brand Partnerships
Park brings over 20 years of industry experience to expand innovation and drive brand partner growth ROMEOVILLE, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoolie Park as Vice President of Brand Partnerships. In this role, Park will lead strategic relationships with emerging and established beauty brands, expanding Solésence's ability to deliver fully integrated, turnkey solutions that accelerate speed to market while enabling brands to deploy more working capital toward marketing and growth initiatives. "We are incredibly e
116dINSIDER
Director Whitmore R Janet bought $4,787 worth of shares (2,500 units at $1.91), increasing direct ownership by 0.12% to 2,086,698 units (SEC Form 4)
4 - SOLESENCE, INC. (0000883107) (Issuer)
135dINSIDER
Director Whitmore R Janet bought $63,274 worth of shares (35,056 units at $1.80), increasing direct ownership by 2% to 2,084,198 units (SEC Form 4)
4 - SOLESENCE, INC. (0000883107) (Issuer)
144dSEC
Solesence Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
145dSEC
Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
164dSEC
Solesence Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
164dSEC
SEC Form 10-Q filed by Solesence Inc.
10-Q - SOLESENCE, INC. (0000883107) (Filer)
165dPR
Solésence Reports Third Quarter 2025 Financial Results
Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2025. Recent Highlights and Accomplishments Continued strategic transformation to drive future innovation and growth with promotion of Kevin Cureton to President and Chief Executive Officer.Appointed Laura Riffner, a seasoned financial and operations expert, as Chief Financial Officer to lead accounting and finan
166dPR
Solésence, Inc. Appoints Yoana Dvorzsak as Vice President of Innovation and Product Integrity
Dvorzsak to oversee product quality and drive innovation to support growth amidst evolving consumer needs; Named a Cosmetic Executive Women (CEW) Innovator Honoree ROMEOVILLE, Ill., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoana Dvorzsak to the newly created role of Vice President of Innovation and Product Integrity to support the Company's continued innovation and operational excellence in its new phase of growth. Dvorzsak will lead a newly unified group that combines Solésence's research and development, product and component de
170dSEC
Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
177dPR
Solésence To Report Third Quarter 2025 Financial Results and Host a Conference Call
ROMEOVILLE, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third quarter of 2025 before the market opens on Tuesday, November 11, 2025, and host a conference call and webcast on the same date. Third Quarter 2025 Conference Call DetailsDate / Time: Tuesday, November 11, 2025 – 7:30 a.m. CDT, 8:30 a.m. EDT Speakers: Kevin Cureton, President & CEO, Laura Riffner, Chief Financial Officer, and Jess Jankowski, Board Advisor Webcast Link: https://edge.media-server.com/mmc/p/qur8mp24 Dial-In Link: https://registe
201dINSIDER
SEC Form 3 filed by new insider Riffner Laura C
3 - SOLESENCE, INC. (0000883107) (Issuer)
233dSEC
Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
234dPR
Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth
ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company's expansion and innovation, will assume the role of President and Chief Executive Officer. Laura Riffner has been appointed Chief Financial Officer, bringing decades of financial expertise in enhancing operational excellence and efficiency. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company
239dSEC
Solesence Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - SOLESENCE, INC. (0000883107) (Filer)
254dSEC
SEC Form 10-Q filed by Solesence Inc.
10-Q - SOLESENCE, INC. (0000883107) (Filer)
268dSEC
Solesence Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - SOLESENCE, INC. (0000883107) (Filer)
268dPR
Solésence Reports Second Quarter 2025 Financial Results
ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025. Recent Highlights and Accomplishments Joined broad-market Russell 3000® and small-cap Russell 2000® IndexesAmended loan agreements to fuel growth initiatives "During our seasonally highest-performing quarter, we're pleased with the effectiveness of our commercial execution and the consistent, on-time delivery of products to our partners," said Jess Jankowski, President and Chief Executive Officer of Solésence. "Innovation
269dSEC
SEC Form DEF 14A filed by Solesence Inc.
DEF 14A - SOLESENCE, INC. (0000883107) (Filer)
275dPR
Solésence To Report Second Quarter 2025 Financial Results and Host a Conference Call
ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the second quarter of 2025 after the market close on Thursday, July 31, 2025, and host a conference call and webcast on the same date. Second Quarter 2025 Conference Call Details Date / Time: Thursday, July 31, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/7n5uumgk Dial-In Link: https://register-conf.media-server.com/register/